Free Trial

IQVIA (IQV) Stock Forecast & Price Target

IQVIA logo
$187.88 +1.91 (+1.03%)
As of 09:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
6
Buy
18

Based on 24 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 6 have given a hold rating, and 18 have given a buy rating for IQV.

Consensus Price Target

$229.64
22.23% Upside
According to the 24 analysts' twelve-month price targets for IQVIA, the average price target is $229.64. The highest price target for IQV is $276.00, while the lowest price target for IQV is $160.00. The average price target represents a forecasted upside of 22.23% from the current price of $187.88.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

TypeCurrent Forecast
9/17/24 to 9/17/25
1 Month Ago
8/18/24 to 8/18/25
3 Months Ago
6/19/24 to 6/19/25
1 Year Ago
9/18/23 to 9/17/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
18 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
12 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$229.64$228.62$226.32$266.67
Forecasted Upside22.23% Upside18.71% Upside46.36% Upside11.12% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside22.82% Upside17,138.08% Upside11.50% Upside
News Sentiment Rating
Positive News

See Recent IQV News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/9/2025Jefferies Financial Group
2 of 5 stars
David Windley
David Windley
Not Rated
UpgradeHoldBuy$195.00 ➝ $225.00+19.86%
9/3/2025Redburn Partners
3 of 5 stars
Jamie Clark
Not Rated
Set Target$214.00+17.92%
7/25/2025Mizuho
3 of 5 stars
Ann Hynes
Ann Hynes
3 of 5 stars
Boost TargetOutperform$190.00 ➝ $225.00+13.90%
7/23/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
7/23/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$185.00 ➝ $225.00+15.70%
7/23/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
7/23/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$209.00 ➝ $235.00+22.12%
7/23/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$165.00 ➝ $185.00-1.54%
7/23/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$159.00 ➝ $196.00+4.32%
7/9/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$170.00 ➝ $180.00+9.30%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral
5/19/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$232.00 ➝ $177.00+25.40%
4/25/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
4/25/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$260.00 ➝ $160.00+6.17%
2/11/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$245.00 ➝ $250.00+24.05%
2/10/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$270.00 ➝ $270.00+31.00%
2/7/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$273.00 ➝ $261.00+24.95%
2/3/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
12/20/2024Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$250.00+30.53%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$255.00 ➝ $235.00+17.54%
11/19/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$260.00 ➝ $248.00+28.58%
11/1/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$270.00 ➝ $265.00+27.09%
11/1/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$270.00 ➝ $255.00+22.30%
11/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$280.00 ➝ $250.00+20.00%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$276.00+20.32%
7/31/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:50 AM ET.


Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • The current stock price is around $191, reflecting a strong market position and investor interest in the company's services.
  • IQVIA Holdings Inc. provides advanced analytics and technology solutions, which are increasingly in demand in the life sciences industry, indicating potential for growth.
  • Recent insider transactions show confidence from company executives, as they continue to hold significant shares even after selling portions of their holdings.
  • The company operates in multiple regions, including the Americas, Europe, Africa, and the Asia-Pacific, diversifying its revenue streams and reducing risk.
  • With a focus on clinical research services, IQVIA is well-positioned to benefit from the ongoing advancements in healthcare and pharmaceuticals.

IQVIA
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • Insider sales, such as those by Keriann Cherofsky and Eric Sherbet, may raise concerns about the company's future performance and could indicate a lack of confidence among executives.
  • Insiders own only 1.60% of the company's stock, which may suggest limited alignment between management and shareholder interests.
  • The recent decrease in insider ownership percentages could signal potential volatility in stock performance, which may deter risk-averse investors.
  • Market conditions can be unpredictable, and the life sciences sector may face regulatory challenges that could impact IQVIA's operations and profitability.
  • As the company continues to grow, it may face increased competition from other firms in the analytics and clinical research space, potentially affecting its market share.

IQV Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $229.64, with a high forecast of $276.00 and a low forecast of $160.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 6 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 22.23% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 1 upgrade by analysts.

IQVIA has been rated by research analysts at Barclays, Cowen, Evercore ISI, Jefferies Financial Group, Mizuho, Redburn Partners, Robert W. Baird, Truist Financial, UBS Group, and William Blair in the past 90 days.

Analysts like IQVIA less than other "medical" companies. The consensus rating score for IQVIA is 2.75 while the average consensus rating score for "medical" companies is 2.78. Learn more on how IQV compares to other companies.


This page (NYSE:IQV) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners